Spots Global Cancer Trial Database for recurrent prostate carcinoma

Every month we try and update this database with for recurrent prostate carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer	NCT02522715	Castration-Resi... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Cabazitaxel Enzalutamide Laboratory Biom... Pharmacological... Prednisone	18 Years -	OHSU Knight Cancer Institute
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer	NCT01120236	Prostate Adenoc... Recurrent Prost... Stage IV Prosta...	Bicalutamide Cixutumumab Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases	NCT00936975	Hormone-Resista... Metastatic Mali... Recurrent Prost... Stage IV Prosta...	Fluorine F 18 S...	18 Years -	National Cancer Institute (NCI)
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer	NCT03796767	Recurrent Prost... Metastatic Mali... Metastatic Mali... Oligometastasis Prostate Adenoc... PSA Failure	Hypofractionate... Intensity-Modul... Metastasectomy Quality-of-Life... Questionnaire A... Stereotactic Bo...	18 Years -	University of Utah
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement	NCT00869206	Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic...	zoledronic acid	18 Years -	Alliance for Clinical Trials in Oncology
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	NCT01576172	Castration-Resi... Recurrent Prost... Stage IV Prosta...	Abiraterone Ace... Laboratory Biom... Prednisone Veliparib	18 Years -	National Cancer Institute (NCI)
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy	NCT02099864	Castration-Resi... Metastatic Mali... Metastatic Mali... Metastatic Pros... Recurrent Prost... Stage III Prost... Stage IV Prosta...	Enzalutamide	18 Years -	OHSU Knight Cancer Institute
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer	NCT01120236	Prostate Adenoc... Recurrent Prost... Stage IV Prosta...	Bicalutamide Cixutumumab Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement	NCT00869206	Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic...	zoledronic acid	18 Years -	Alliance for Clinical Trials in Oncology
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	NCT01576172	Castration-Resi... Recurrent Prost... Stage IV Prosta...	Abiraterone Ace... Laboratory Biom... Prednisone Veliparib	18 Years -	National Cancer Institute (NCI)
Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery	NCT03515577	Recurrent Prost...	Computed Tomogr... Fluciclovine F1... Gallium Ga 68-l... Laboratory Biom... Positron Emissi...	19 Years -	Jonsson Comprehensive Cancer Center
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T	NCT01833208	Hormone-Resista... Metastatic Mali... Recurrent Prost... Stage IV Prosta...	Laboratory Biom... Radiation Thera...	18 Years -	Roswell Park Cancer Institute
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment	NCT02673151	Prostate Adenoc... PSA Failure Recurrent Prost...	Computed Tomogr... 68Ga-PSMA-11 Positron Emissi...	18 Years -	Stanford University
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	NCT01503229	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Abiraterone Ace... Laboratory Biom... Pharmacological... Prednisone	18 Years -	University of Washington
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer	NCT00170157	Prostate Adenoc... Prostate Carcin... Recurrent Prost... Stage III Prost... Stage IV Prosta...	Bicalutamide Flutamide Goserelin Aceta... Ipilimumab Leuprolide Acet... Pharmacological...	18 Years -	Mayo Clinic
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer	NCT02881242	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Laboratory Biom... Quality-of-Life... Trametinib	18 Years -	Jonsson Comprehensive Cancer Center
Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation	NCT02899221	Recurrent Prost...	High-Dose Rate ... Hyperthermia Tr... Laboratory Biom...	18 Years -	Thomas Jefferson University
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer	NCT01786265	Prostate Adenoc... Recurrent Prost...	Abiraterone Ace... Bicalutamide Degarelix Flutamide Goserelin Aceta... Leuprolide Acet... Nilutamide Prednisone	18 Years -	M.D. Anderson Cancer Center
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer	NCT05779943	Prostate Adenoc... Recurrent Prost...	Furosemide F18-rhPSMA-7.3 Positron Emissi... Computed Tomogr...	18 Years -	Emory University
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer	NCT01050504	Localized Renal... Malignant Solid... Metastatic Mali... Metastatic Mali... Metastatic Rena... Recurrent Bladd... Recurrent Prost... Recurrent Renal... Stage IV Bladde... Stage IV Bladde... Stage IV Prosta...	Cytology Specim... Laboratory Biom...	18 Years -	University of Washington
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer	NCT02206334	Male Breast Car... Prostate Adenoc... Recurrent Breas... Recurrent Non-S... Recurrent Prost... Stage IV Breast... Stage IV Non-Sm... Stage IV Prosta...	Stereotactic Bo...	18 Years -	NRG Oncology
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer	NCT02488070	Recurrent Prost...	Computed Tomogr... Gallium Ga 68-l... Magnetic Resona... Positron Emissi...	18 Years -	Stanford University
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	NCT02159950	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Laboratory Biom... Sipuleucel-T Tasquinimod	18 Years -	Roswell Park Cancer Institute
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide	NCT02228265	Castration Leve... Castration-Resi... Prostate Adenoc... PSA Progression Recurrent Prost... Stage IV Prosta...	Cytology Specim... Enzalutamide Laboratory Biom...	-	OHSU Knight Cancer Institute
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel	NCT01253642	Hormone-Resista... Metastatic Pros... Prostate Adenoc... Recurrent Prost...	Biopsy of Prost... Docetaxel Laboratory Biom... Phenelzine Sulf...	18 Years -	OHSU Knight Cancer Institute
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide	NCT02312557	Castration-Resi... Hormone-Resista... PSA Progression Recurrent Prost... Stage IV Prosta...	Enzalutamide Laboratory Biom... Pembrolizumab	18 Years -	OHSU Knight Cancer Institute
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	NCT02159950	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Laboratory Biom... Sipuleucel-T Tasquinimod	18 Years -	Roswell Park Cancer Institute
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer	NCT05034562	Metastatic Pros... Recurrent Prost... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Computed Tomogr... Gallium Ga 68-l... Magnetic Resona... Positron Emissi...	18 Years -	M.D. Anderson Cancer Center
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy	NCT02940262	Prostate Adenoc... Recurrent Prost...	Gallium Ga 68 G... Laboratory Biom... Positron Emissi...	-	Jonsson Comprehensive Cancer Center
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer	NCT05779943	Prostate Adenoc... Recurrent Prost...	Furosemide F18-rhPSMA-7.3 Positron Emissi... Computed Tomogr...	18 Years -	Emory University
Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer	NCT03122743	Hormone-Resista... Recurrent Prost... Stage I Prostat... Stage II Prosta... Stage IIA Prost... Stage IIB Prost...	Biospecimen Col... Laboratory Biom... Questionnaire A...	18 Years -	Wake Forest University Health Sciences
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer	NCT01787331	Prostate Adenoc... Recurrent Prost... Stage I Prostat... Stage II Prosta... Stage III Prost...	Itraconazole Laboratory Biom... Pharmacological...	18 Years -	University of California, San Francisco
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation	NCT04457232	Metastatic Mali... Prostate Carcin... Recurrent Prost...	Computed Tomogr... Gallium Ga 68 F... Positron Emissi...	18 Years -	Jonsson Comprehensive Cancer Center
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer	NCT01251861	Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost...	Akt Inhibitor M... Bicalutamide Clinical Observ... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer	NCT02807805	Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Abiraterone Ace... Niclosamide Prednisone	19 Years -	University of California, Davis
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer	NCT00064129	Recurrent Prost... Stage IV Prosta...	Ipilimumab Laboratory Biom... Pharmacological... Sargramostim	18 Years -	National Cancer Institute (NCI)
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer	NCT03501940	Prostate Adenoc... PSA Level Great... PSA Level Great... PSA Progression Recurrent Prost...	Computed Tomogr... Fluorine F 18 D... Laboratory Biom... Positron Emissi...	18 Years -	Stanford University
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer	NCT00064129	Recurrent Prost... Stage IV Prosta...	Ipilimumab Laboratory Biom... Pharmacological... Sargramostim	18 Years -	National Cancer Institute (NCI)
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies	NCT02985021	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Carboplatin Docetaxel	18 Years -	Seattle Institute for Biomedical and Clinical Research
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer	NCT02881242	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Laboratory Biom... Quality-of-Life... Trametinib	18 Years -	Jonsson Comprehensive Cancer Center
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy	NCT01953640	Hormone-Resista... Metastatic Pros... Prostate Adenoc... Recurrent Prost...	Laboratory Biom... Quality-of-Life...	18 Years -	Mayo Clinic
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy	NCT02940262	Prostate Adenoc... Recurrent Prost...	Gallium Ga 68 G... Laboratory Biom... Positron Emissi...	-	Jonsson Comprehensive Cancer Center
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer	NCT03501940	Prostate Adenoc... PSA Level Great... PSA Level Great... PSA Progression Recurrent Prost...	Computed Tomogr... Fluorine F 18 D... Laboratory Biom... Positron Emissi...	18 Years -	Stanford University
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer	NCT03698370	Prostate Adenoc... PSA Progression Recurrent Prost...	Gallium Ga 68 D... Gallium Ga 68 P...	18 Years -	Stanford University
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers	NCT05722288	Localized Prost... Locally Advance... Locally Advance... Malignant Solid... Recurrent Prost... Stage I Prostat... Stage IB Cervic... Stage IB2 Cervi... Stage II Prosta... Stage II Rectal... Stage IIA Cervi... Stage IIB Cervi... Stage III Prost... Stage III Recta... Stage IIIA Cerv... Stage IIIB Cerv... Stage IIIC Cerv... Stage IVA Prost...	Biospecimen Col... Informational I... Quality-of-Life... Questionnaire A... Short-Term Fast...	18 Years -	City of Hope Medical Center
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer	NCT05034562	Metastatic Pros... Recurrent Prost... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost...	Computed Tomogr... Gallium Ga 68-l... Magnetic Resona... Positron Emissi...	18 Years -	M.D. Anderson Cancer Center
PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma	NCT01304485	Prostate Cancer	Sodium Acetate ...	18 Years -	Phoenix Molecular Imaging
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer	NCT03501940	Prostate Adenoc... PSA Level Great... PSA Level Great... PSA Progression Recurrent Prost...	Computed Tomogr... Fluorine F 18 D... Laboratory Biom... Positron Emissi...	18 Years -	Stanford University
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer	NCT04857502	Prostate Carcin... Recurrent Prost...	99mTc-based PSM... Computed Tomogr... Single Photon E...	-	Jonsson Comprehensive Cancer Center
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy	NCT01953640	Hormone-Resista... Metastatic Pros... Prostate Adenoc... Recurrent Prost...	Laboratory Biom... Quality-of-Life...	18 Years -	Mayo Clinic
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy	NCT01953640	Hormone-Resista... Metastatic Pros... Prostate Adenoc... Recurrent Prost...	Laboratory Biom... Quality-of-Life...	18 Years -	Mayo Clinic
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy	NCT00486642	Hormone-Resista... Recurrent Prost...	Bicalutamide Laboratory Biom... Pazopanib Hydro... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases	NCT00936975	Hormone-Resista... Metastatic Mali... Recurrent Prost... Stage IV Prosta...	Fluorine F 18 S...	18 Years -	National Cancer Institute (NCI)
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer	NCT01050504	Localized Renal... Malignant Solid... Metastatic Mali... Metastatic Mali... Metastatic Rena... Recurrent Bladd... Recurrent Prost... Recurrent Renal... Stage IV Bladde... Stage IV Bladde... Stage IV Prosta...	Cytology Specim... Laboratory Biom...	18 Years -	University of Washington
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer	NCT02935205	Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Enzalutamide Indomethacin	19 Years -	University of California, Davis
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer	NCT03698370	Prostate Adenoc... PSA Progression Recurrent Prost...	Gallium Ga 68 D... Gallium Ga 68 P...	18 Years -	Stanford University
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer	NCT01050504	Localized Renal... Malignant Solid... Metastatic Mali... Metastatic Mali... Metastatic Rena... Recurrent Bladd... Recurrent Prost... Recurrent Renal... Stage IV Bladde... Stage IV Bladde... Stage IV Prosta...	Cytology Specim... Laboratory Biom...	18 Years -	University of Washington
Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment	NCT04190446	Metastatic Pros... Oligometastatic... Prostate Adenoc... Recurrent Prost... Stage IV Prosta...	Intensity-Modul... Proton Beam Rad... Quality-of-Life... Questionnaire A... Computed Tomogr... Magnetic Resona... Biospecimen Col...	18 Years -	Mayo Clinic
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer	NCT02499835	Hormone-Resista... Metastatic Mali... Metastatic Mali... Metastatic Pros... Prostate Adenoc... Recurrent Prost... Stage IV Prosta...	Pembrolizumab pTVG-HP Plasmid...	18 Years -	University of Wisconsin, Madison
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer	NCT03902951	Metastatic Pros... Prostate Adenoc... Recurrent Prost... Stage IVB Prost...	Abiraterone Ace... Apalutamide Leuprolide Acet... Quality-of-Life... Questionnaire A... Stereotactic Bo...	18 Years -	Jonsson Comprehensive Cancer Center
SMMART Adaptive Clinical Treatment (ACT) Trial	NCT05238831	Advanced Breast... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Prosta... Advanced Sarcom... Anatomic Stage ... Anatomic Stage ... Recurrent Adult... Recurrent Breas... Recurrent Ovari... Recurrent Prost... Stage II Pancre... Stage III Ovari... Stage III Pancr... Stage IV Ovaria... Stage IV Pancre...	Alectinib Alpelisib Anastrozole Atezolizumab Bevacizumab Biopsy Biospecimen Col... Capecitabine Carboplatin Cobimetinib Entrectinib Eribulin Fulvestrant Hyaluronidase-z... Irinotecan Letrozole Nab-paclitaxel Niraparib Olaparib Paclitaxel Palbociclib Pertuzumab Quality-of-Life... Trastuzumab Trastuzumab Emt... Vemurafenib Vinorelbine Vismodegib	18 Years -	OHSU Knight Cancer Institute
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	NCT01576172	Castration-Resi... Recurrent Prost... Stage IV Prosta...	Abiraterone Ace... Laboratory Biom... Prednisone Veliparib	18 Years -	National Cancer Institute (NCI)
Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment	NCT04190446	Metastatic Pros... Oligometastatic... Prostate Adenoc... Recurrent Prost... Stage IV Prosta...	Intensity-Modul... Proton Beam Rad... Quality-of-Life... Questionnaire A... Computed Tomogr... Magnetic Resona... Biospecimen Col...	18 Years -	Mayo Clinic
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide	NCT02312557	Castration-Resi... Hormone-Resista... PSA Progression Recurrent Prost... Stage IV Prosta...	Enzalutamide Laboratory Biom... Pembrolizumab	18 Years -	OHSU Knight Cancer Institute
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer	NCT00064129	Recurrent Prost... Stage IV Prosta...	Ipilimumab Laboratory Biom... Pharmacological... Sargramostim	18 Years -	National Cancer Institute (NCI)
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer	NCT02206334	Male Breast Car... Prostate Adenoc... Recurrent Breas... Recurrent Non-S... Recurrent Prost... Stage IV Breast... Stage IV Non-Sm... Stage IV Prosta...	Stereotactic Bo...	18 Years -	NRG Oncology
Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment	NCT04190446	Metastatic Pros... Oligometastatic... Prostate Adenoc... Recurrent Prost... Stage IV Prosta...	Intensity-Modul... Proton Beam Rad... Quality-of-Life... Questionnaire A... Computed Tomogr... Magnetic Resona... Biospecimen Col...	18 Years -	Mayo Clinic
PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma	NCT01304485	Prostate Cancer	Sodium Acetate ...	18 Years -	Phoenix Molecular Imaging
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer	NCT02206334	Male Breast Car... Prostate Adenoc... Recurrent Breas... Recurrent Non-S... Recurrent Prost... Stage IV Breast... Stage IV Non-Sm... Stage IV Prosta...	Stereotactic Bo...	18 Years -	NRG Oncology
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations	NCT02646319	Advanced Malign... Cervical Squamo... Endometrial Car... Malignant Uteri... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Head ... Recurrent Malig... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Solid Neoplasm Stage III Bladd... Stage III Prost... Stage III Renal... Stage IIIA Brea... Stage IIIA Cerv... Stage IIIA Ovar... Stage IIIB Brea... Stage IIIB Cerv... Stage IIIB Ovar... Stage IIIC Brea... Stage IIIC Ovar... Stage IV Breast... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IVA Bladd... Stage IVA Cervi... Stage IVB Bladd... Stage IVB Cervi...	Laboratory Biom... Nanoparticle Al... Quality-of-Life...	18 Years -	Mayo Clinic
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer	NCT03123978	Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Enzalutamide Niclosamide	19 Years -	University of California, Davis
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	NCT01503229	Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta...	Abiraterone Ace... Laboratory Biom... Pharmacological... Prednisone	18 Years -	University of Washington
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer	NCT03796767	Recurrent Prost... Metastatic Mali... Metastatic Mali... Oligometastasis Prostate Adenoc... PSA Failure	Hypofractionate... Intensity-Modul... Metastasectomy Quality-of-Life... Questionnaire A... Stereotactic Bo...	18 Years -	University of Utah

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: